Skip Navigation


Susan A. Melin, M.D.Wake Forest Baptist Health

Doctor Rating

4.6 out of 5

127 Ratings

Susan A. Melin, M.D.


Clinical Interests

Breast Cancer

Contact Information

Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of North Carolina-Chapel Hill, 1977
  • M.D., WFU School of Medicine, 1985
  • Residency, Eastern Virginia Med School, 1988
  • Fellowship, Univ of NC at Chapel Hill, 1991

Board Certifications

  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Medical Oncology


  • North Carolina Medical Society
  • Am Coll Of Physicians
  • Am Medical Assn
  • Am Soc of Clinical Oncology

NPI Number

  • 1528042058
Susan A. Melin, M.D.

Doctor Rating

4.6 out of 5

127 Ratings

Susan A. Melin, M.D.

Professor, Hematology & Oncology
Office of Women in Medicine and Science

Research Interests

Anthracyclines; Breast Neoplasms; Thalidomide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols
More »

Contact Information

Academic: 336-716-7975 | Department: 336-716-4464

Recent Publications

Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bageman E, D'Agostino RB Jr, Ver Hoeve ES, Esserman L, Cigler T.. JAMA. 2017;317(6):606-614.

Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Rugo HS, Melin SA, Voigt J.. Breast Cancer Res Treat. 2017;163(2):199-205.

African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013 [abstract]. Thomas A, Altekruse S, Avery TP, Melin SA, Howard-McNatt MM, Schroeder MC.. Cancer Res. 2017;77(Suppl 4):P5-10-02.

The Thrive Study: feasibility of an intervention to prevent weight gain in breast cancer survivors during chemotherapy [abstract]. Mihalko SL, Yax A, Oliver S, Miller G, Melin S, Avery T, Hopkins J, Russell G, Brubaker P.. Ann Behav Med. 2017;51(Suppl 1):S1453-1454.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA.. Cancer Biol Ther. 2015;16(5):678-683.

Weight loss intervention in survivors of ER/PR-negative breast cancer. Vitolins MZ, Milliron BJ, Hopkins JO, Fulmer A, Lawrence J, Melin S, Case D.. Clin Med Insights Womens Health. 2014;7():17-24.

Does age predict outcome in patients with inflammatory breast cancer?. Ahmed S, Lawrence J, Stewart JH, Melin S, Levine EA, Howard-McNatt M.. Am Surg. 2014;80(8):E221-E224.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease [abstract]. Cowherd S, Melin S, Akman S, Cole J, Lawrence J.. Cancer Res. 2014;74(19 Suppl):CT302.

Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH IV.. Am J Surg. 2013;205(4):397-401.

The Dignicap System to prevent alopecia in women receiving chemotherapy for breast cancer [abstract]. Rugo HS, Serrurier K, Melisko M, Glencer A, Hwang J, D'Agostino R, Hutchens S, Esserman L, Melin S.. Breast. 2013;22(Suppl 1):S119.

Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG.. Cancer Biol Ther. 2013;14(6):476-480.

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG.. JACC Cardiovasc Imaging. 2013;6(8):877-885.

Aortic stiffness increases upon receipt of anthracycline chemotherapy. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. J Clin Oncol. 2010;28(1):166-172.

Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG.. J Clin Oncol. 2010;28(15 Suppl):e19524.

Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W.. Circulation. 2010;122(21 Suppl):A12766.

Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. Circulation. 2009;120(18 Suppl):S299.

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, et al.. Cancer Chemother Pharmacol. 2008;61(3):453-458.

Phase I study of lenalidomide in solid tumors. Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA.. J Thorac Oncol. 2007;2(5):445-449.

Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.

Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al.. Br J Cancer. 2006;95(3):260-265.

Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA.. Int J Gastrointest Cancer. 2006;37(1):7-14.

Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Breast Cancer
Susan A. Melin, M.D.

Susan A. Melin, M.D.

Professor, Hematology & Oncology
Office of Women in Medicine and Science

Doctor Rating

4.6 out of 5

Susan A. Melin, M.D.127 Ratings


Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
CP efforts to include in decisions
CP explanations of prob/condition
CP spoke using clear language
Friendliness/courtesy of CP
Likelihood of recommending CP
Patients' confidence in CP
Time CP spent with patient
Wait time at clinic

Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.


She's fantastic


I live over 2 hours away, but gladly travel to see Dr.Melin. she provides great care I appreciate that she is kind and caring. She is always willing to work with with my husbands schedule, so that he can accompany me.




Dr Melin is always on top of my needs on regards of my health, every time I had a question I get an answer right away and if there is a need for anything she makes sure I get what I need to get better


Dr Melin is fantastic!


Dr Melin has twice considerably extended my life. I am glad she is my oncologist.


Dr. Melin is very good.


Love love *Dr. Susan Melin. I drive 3 hours to see her.


Dr Melin is a great oncologist and always includes me in decisions regarding my health and treatment.


My mother is deceased, I am an only child, being told you have cancer is very devastating. *Dr. Melin was very comforting, her care & concern felt motherly.


Remember that this is all happening to me for the first time. I don't want someone to casually talk about removing my breasts in a matter of fact way. I don't want to be asked repeatedly whether or not I want a flu shot when I have said no to the shot. I have heard that Melin is an excellent doctor but her bedside manner needs improvement. I agree.

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsMagnet Hospital RecognitionJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.